Polar Asset Management Partners Inc. Sells 4,582 Shares of Repligen Corporation $RGEN

Key Points

• Polar Asset Management Partners Inc. reduced its holdings in Repligen Corporation by 66.4%, now owning 2,318 shares valued at approximately $295,000.
• Several institutional investors have increased or acquired stakes in Repligen, with 97.64% of the stock being owned by these investors.
• Repligen Corporation reported a quarterly earnings miss with $0.37 EPS, below the consensus estimate of $0.40, despite a 14.8% year-over-year revenue increase to $182.37 million.

Polar Asset Management Partners Inc. cut its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 66.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,318 shares of the biotechnology company's stock after selling 4,582 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Repligen were worth $295,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of RGEN. Point72 Asset Management L.P. increased its stake in shares of Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock worth $962,711,000 after acquiring an additional 430,039 shares during the last quarter. Nuveen LLC acquired a new position in shares of Repligen in the first quarter worth $35,536,000. Artemis Investment Management LLP increased its stake in shares of Repligen by 110.1% in the first quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock worth $41,128,000 after acquiring an additional 169,397 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Repligen by 17,721.1% in the first quarter. GAMMA Investing LLC now owns 121,896 shares of the biotechnology company's stock worth $15,510,000 after acquiring an additional 121,212 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

RGEN stock traded down $4.82 during mid-day trading on Friday, reaching $114.70. 223,764 shares of the stock traded hands, compared to its average volume of 771,531. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The business has a 50-day moving average of $121.01 and a two-hundred day moving average of $128.35. The firm has a market capitalization of $6.45 billion, a PE ratio of -459.66, a P/E/G ratio of 2.21 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter last year, the company earned $0.40 earnings per share. The firm's revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on RGEN shares. Barclays started coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target on the stock. Jefferies Financial Group decreased their price objective on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a report on Friday. Evercore ISI decreased their price objective on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company decreased their price objective on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $166.67.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.